N

Nuclidium

Biotech & Life Sciences · Basel, Switzerland · Founded 2017

Nuclidium AG is a clinical-stage biotechnology company specializing in the development of copper-based radiopharmaceuticals. The firm is focused on creating a new standard in precision oncology by developing next-generation solutions for both the diagnosis and treatment of cancer, a concept known as theranostics. The company's platform is centered on the use of copper isotopes, specifically 61Cu for PET imaging (diagnosis) and 67Cu for therapy. This approach reportedly offers significant advantages, including higher absorption of the agent by tumors and safer radiation profiles for patients. Nuclidium is advancing a pipeline of these targeted radiopharmaceuticals and has announced positive Phase 1 results for its novel PET imaging agent, 61Cu-NuriPro. The business model appears to be focused on research and development, advancing its product pipeline through clinical trials. To support this, the company engages in strategic partnerships, such as its collaboration with Guerbet, to further the development and potential commercialization of its targeted copper-based radiotheranostics. The company operates in the specialized and high-growth market of radiopharmaceuticals and precision oncology. Keywords: Radiopharmaceuticals, Theranostics, Precision Oncology, Copper Isotopes, Cancer Diagnosis, Cancer Treatment, Clinical-Stage, Biotechnology, PET Imaging, 67Cu